Is the network meta-analysis (NETMA) bringing us closer to the truth? insights from recent antithrombotic drug data

Thrombosis and Haemostasis

Volumn 108, Issue 5, 2012, Pages 872-875

  Schulman, Sam ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; WARFARIN;

ARTICLE; BLEEDING; DEATH; DRUG EFFICACY; DRUG SAFETY; HIP ARTHROPLASTY; HUMAN; KNEE ARTHROPLASTY; META ANALYSIS (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RISK; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; HUMANS;

EID: 84870047587     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-10-0730     Document Type: Article

References (20)

1. Holmes M, Carroll C, Papaioannou D. Dabigatran etexilate for the prevention of venous thromboem-bolism in patients undergoing elective hip and knee surgery: a single technology appraisal. Health Tech-nol Assess 2009;13 (Suppl 2): 55-62.
2. McCullagh L, Tilson L, Walsh C, et al. A cost-effectiveness model comparing rivaroxaban and dabig-atran etexilate with enoxaparin sodium as throm-boprophylaxis after total hip and total knee replacement in the irish healthcare setting. Pharmacoeco-nomics 2009; 27: 829-846.
3. Wolowacz SE, Roskell NS, Maciver F, et al. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery. Clin Ther 2009; 31: 194-212.
4. Wolowacz SE, Roskell NS, Plumb JM, et al. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement. Thromb Haemost 2010; 103: 360-371.
5. Matchar DB, Jacobson A, Dolor R, et al. Effect of home testing of international normalized ratio on clinical events. N Engl J Med 2010; 363: 1608-1620.
6. Harenberg J, Marx S, Dahl OE, et al. Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery. Thromb Haemost 2012; 108: 903-912.
7. Cohen A, Drost P, Marchant N, et al. The efficacy and safety of pharmacological prophylaxis of venous thromboembolism following elective nnee or hip replacement: systematic review and network meta-analysis. Clin Appl Thromb Hemost 2012; Epub ahead of print.
8. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372: 31-39.
9. Eriksson BI, Borris LC, Dahl OE, et al. Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Res 2007; 120: 685-693.
10. Maratea D, Fadda V, Trippoli S, et al. Prevention of venous thromboembolism after major orthopedic surgery: indirect comparison of three new oral anticoagulants. J Thromb Haemost 2011; 9: 1868-1870.
11. Gomez-Outes A, Terleira-Fernandez AI, Suarez-Gea ML, et al. Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. Br Med J 2012; 344: e3675.
12. Guyatt GH, Norris SL, Schulman S, et al. Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Anti-thrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): 53S-70S.
13. Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e278S-e325S.
14. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigat-ran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 949-956.
15. Eriksson BI, Borris LC, Friedman RJ, et al. Rivarox-aban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-2775.
16. Roskell NS, Lip GY, Noack H, et al. Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus da-bigatran etexilate. Thromb Haemost 2010; 104: 1106-1115.
17. Lip GY, Larsen TB, Skjøth F, et al. Indirect comparisons of new oral anticoagulant drugs for efficacy a n d safet y when used for st roke preve ntion in a trial fibrillation. J Am Coll Cardiol 2012; 60: 738-746.
18. Mantha S, Ansell J. An indirect comparison of da-bigatran, rivaroxaban and apixaban for atrial fibrillation. Thromb Haemost 2012; 108: 476-484.
19. Harenberg J, Marx S, Diener HC, et al. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis. Int Angiol 2012; 31: 330-339.
20. Skjøth F, Larsen TB, Rasmussen LH. Indirect comparison studies - are they useful? Insights from the novel oral anticoagulants for stroke prevention in atrial fibrillation. Thromb Haemost 2012; 108: 405-406.